Biomarker-based Therapy for NSCLC: Improving Collaboration, Communication, and Care for ONS Chapters

Targeted therapies have revolutionized the treatment of non-small cell lung cancer (NSCLC) with actionable genetic alterations. The rates of 5-year survival have improved dramatically over the past 10 years with improved early detection methods and the approval of highly effective targeted therapies. Despite advances in NSCLC, the importance and implications of comprehensive biomarker testing for treatment selection and the rapidly evolving evidence of new and emerging targeted agents often present challenges for busy oncology nurses.

Join us for an expert-led session to discuss the role of biomarker testing, emerging data for novel agents, and practical strategies to mitigate common adverse events associated with targeted therapies while also providing strategies to activate and engage patients in their treatment care.